The Importance of Serum Prostate-specific Antigen Testing Frequency in Assessing Biochemical and Clinical Failure After Prostate Cancer Treatment

Urology

Volumn 75, Issue 2, 2010, Pages 467-471

  Ciezki, Jay P ^a   Reddy, Chandana A ^a   Stephenson, Andrew J ^a   Angermeier, Kenneth ^a   Ulchaker, James ^a   Altman, Andrew ^b   Chehade, Nabil ^b   Klein, Eric A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Kaiser Permanente ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CHEMICAL ANALYSIS; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE;

HEMATOLOGIC TESTS; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT FAILURE;

EID: 75349085533     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.08.051     Document Type: Article

References (7)

1. Cox J., Grignon D., Kaplan R., et al. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
2. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
3. Schellhammer P., Cockett A., Boccon-Gibod L., et al. Assessment of endpoints for clinical trials for localized prostate cancer. Urology 49 suppl 4A (1997) 27-38
4. Stephenson A.J., Kattan M.W., Eastham J.A., et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24 (2006) 3973-3978
5. Roach III M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression radiation therapy oncology group 9413. J Clin Oncol 21 (2003) 1904-1911
6. NCCN Practice Guidelines in Oncology -v.2.2007 Prostate Cancer. National Comprehensive Cancer Network, Inc., 2007. http://www.nccn.org/professionals/physicians_gls/PDFprostate.pdf Accessed April 9, 2007
7. Stephenson A.J., Scardino P.T., Kattan M.W., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25 (2007) 2035-2041